LIMINATUS PHARMA, INC. Investment Income, Interest
LIMINATUS PHARMA, INC. (LIMN) reported Investment Income, Interest of $76.59 thousand for the 12-month period ending 2025-12-31, per its S-1 filed 2026-06-24.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-06-24
- LIMINATUS PHARMA, INC. investment income, interest for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- LIMINATUS PHARMA, INC. investment income, interest for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- LIMINATUS PHARMA, INC. investment income, interest for the quarter ending 2025-06-30 was $24.38K, a 3.36% decline year-over-year.
- LIMINATUS PHARMA, INC. investment income, interest for the quarter ending 2025-03-31 was $52.21K.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | $0.00 derived: sum of 2 quarters · filed 2026-06-24 | $24.38K derived: sum of 3 quarters · filed 2026-06-24 | $76.59K S-1 · filed 2026-06-24 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $24.38K derived: sum of 2 quarters · filed 2025-11-14 | $76.59K 10-Q · filed 2025-11-14 | $120.08K derived: sum of 4 quarters · filed 2026-06-24 |
| 2025-06-30 | $24.38K 10-Q · filed 2025-10-06 | $76.59K 10-Q · filed 2025-10-06 | $120.08K derived: sum of 3 quarters · filed 2026-06-24 | $154.56K derived: sum of 4 quarters · filed 2026-06-24 |
| 2025-03-31 | $52.21K S-1 · filed 2026-06-24 | $95.69K derived: sum of 2 quarters · filed 2026-06-24 | $130.18K derived: sum of 3 quarters · filed 2026-06-24 | $155.41K derived: sum of 4 quarters · filed 2026-06-24 |
| 2024-12-31 | $43.49K derived: S-1 12 month − 10-Q 9 month · filed 2026-06-24 | $77.97K derived: sum of 2 quarters · filed 2026-06-24 | $103.20K derived: sum of 3 quarters · filed 2026-06-24 | $122.53K S-1 · filed 2026-06-24 |
| 2024-09-30 | $34.48K 10-Q · filed 2025-11-14 | $59.71K derived: sum of 2 quarters · filed 2025-11-14 | $79.04K 10-Q · filed 2025-11-14 | |
| 2024-06-30 | $25.23K 10-Q · filed 2025-10-06 | $44.56K 10-Q · filed 2025-10-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |